Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting-A Single Center Experience.
COVID-19
chronic kidney disease
molnupiravir
renal transplant
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Oct 2022
31 Oct 2022
Historique:
received:
14
09
2022
revised:
15
10
2022
accepted:
28
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Molnupiravir is approved for the treatment of adult patients with mild to moderate COVID-19. The main goal of the treatment is to reduce hospitalization and mortality rate. This study aimed at the all-cause hospitalization and all-cause death assessment in patients at high risk of severe COVID-19 treated with molnupiravir. This was a prospective, observational single center study. Non-hospitalized patients with SARS-CoV-2 infection, COVID-19 symptoms with the onset of up to 5 days, and at high risk of severe COVID-19 illness received molnupiravir based on attending physician decisions. In total, 107 patients were enrolled. Adverse events were reported in 28.0% of patients, with nausea and abdominal pain being the most commonly observed. No treatment-emergent AEs resulted in therapy discontinuation. Overall, 15 patients required hospitalization. During the observation, 2.8% ( Molnupiravir may be perceived as an alternative treatment for patients with immunosuppression and advanced chronic kidney disease. Nevertheless, further studies are required to conclusively establish a role for molnupiravir in future COVID-19 treatment recommendations.
Sections du résumé
BACKGROUND
BACKGROUND
Molnupiravir is approved for the treatment of adult patients with mild to moderate COVID-19. The main goal of the treatment is to reduce hospitalization and mortality rate. This study aimed at the all-cause hospitalization and all-cause death assessment in patients at high risk of severe COVID-19 treated with molnupiravir.
METHODS
METHODS
This was a prospective, observational single center study. Non-hospitalized patients with SARS-CoV-2 infection, COVID-19 symptoms with the onset of up to 5 days, and at high risk of severe COVID-19 illness received molnupiravir based on attending physician decisions.
RESULTS
RESULTS
In total, 107 patients were enrolled. Adverse events were reported in 28.0% of patients, with nausea and abdominal pain being the most commonly observed. No treatment-emergent AEs resulted in therapy discontinuation. Overall, 15 patients required hospitalization. During the observation, 2.8% (
CONCLUSION
CONCLUSIONS
Molnupiravir may be perceived as an alternative treatment for patients with immunosuppression and advanced chronic kidney disease. Nevertheless, further studies are required to conclusively establish a role for molnupiravir in future COVID-19 treatment recommendations.
Identifiants
pubmed: 36362691
pii: jcm11216464
doi: 10.3390/jcm11216464
pmc: PMC9656557
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Infect Dis. 2022 May 7;22(1):439
pubmed: 35525973
Science. 2021 Sep 24;373(6562):eabj7364
pubmed: 34404735
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
Pharmacol Rep. 2022 Aug 24;:
pubmed: 36001284
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
BMJ. 2022 Mar 2;376:e068632
pubmed: 35236664
Lancet Glob Health. 2022 Mar;10(3):e326-e328
pubmed: 35180408
Pol Arch Intern Med. 2021 Nov 30;131(11):
pubmed: 34845894
Sci Transl Med. 2022 Jan 19;14(628):eabl7430
pubmed: 34941423
Antimicrob Agents Chemother. 2021 Mar 1;:
pubmed: 33649113
J Virol. 2014 Oct;88(20):11886-98
pubmed: 25100843
Clin Infect Dis. 2020 Nov 5;71(8):1962-1968
pubmed: 32472676
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
Nat Microbiol. 2022 Feb;7(2):277-288
pubmed: 35013591
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Ann Med. 2021 Dec;53(1):1419-1428
pubmed: 34482788
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Sci Rep. 2022 Feb 11;12(1):2367
pubmed: 35149742
Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94
pubmed: 33340043
BMJ. 2021 Oct 4;375:n2422
pubmed: 34607801
Am J Transplant. 2022 Oct;22(10):2458-2463
pubmed: 35583664
Am J Transplant. 2020 Nov;20(11):3030-3041
pubmed: 32777153